Vertex has initial success in new diabetes project
Remarkably positive insulin results have arrived from Vertex's first patient in the phase I/II trial of its stem cell therapy against type 1 diabetes.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
The results from the first patient to receive Vertex's treatment for type 1 diabetes, VX-880, a therapy derived from stem cells, have been a cause for celebration for the Boston-based biotech company, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA pauses Swedish diabetes company's phase III trial plans
For subscribers
.jpg&w=384&q=75)
